Literature DB >> 16912011

Cancer associated retinopathy (CAR): An autoimmune-mediated paraneoplastic syndrome.

Nadia Khan1, John J Huang, C Stephen Foster.   

Abstract

Cancer associated retinopathy (CAR) is an uncommon paraneoplastic retinopathy in which antibodies are directed against retinal antigens. Vision loss is associated with abnormal ERG findings. Few case reports and lack of controlled clinical trials make management of this syndrome especially challenging for the clinician. Herein, we describe the clinical, histopathologic and electrophysiologic features of CAR, along with a summary of previously employed management options. Cancer associated retinopathy syndrome has been recognized as a paraneoplastic disorder, most commonly associated with small cell lung cancer, in which cross-reacting autoantibodies against retinal antigen cause retinal dysfunction. Bilateral vision loss as a result of both rod and cone dysfunction in CAR may occur over a period of months, and visual symptoms may precede diagnosis of the systemic malignancy. The heterogeneity in antigens that have been identified as targets of antibody-mediated retinal damage perhaps help to explain the complexity of symptoms and the treatment challenges posed by patients with CAR.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16912011     DOI: 10.1080/08820530500350662

Source DB:  PubMed          Journal:  Semin Ophthalmol        ISSN: 0882-0538            Impact factor:   1.975


  14 in total

1.  Cancer-associated retinopathy presenting as retinal vasculitis with a negative ERG suggestive of on-bipolar cell pathway dysfunction.

Authors:  Anastasios Anastasakis; Andrew D Dick; Erika M Damato; Paul G Spry; Mohamed A Majid
Journal:  Doc Ophthalmol       Date:  2011-06-15       Impact factor: 2.379

2.  Recoverin-associated retinopathy secondary to Warthin tumor of parotid gland.

Authors:  Shigeki Machida; Hiroshi Ohguro; Kazunori Ishida; Masamichi Suzuki; Kazuaki Kawagishi
Journal:  Doc Ophthalmol       Date:  2014-08-23       Impact factor: 2.379

3.  Hyperautofluorescent ring in autoimmune retinopathy.

Authors:  Luiz H Lima; Jonathan P Greenberg; Vivienne C Greenstein; R Theodore Smith; Juliana M F Sallum; Charles Thirkill; Lawrence A Yannuzzi; Stephen H Tsang
Journal:  Retina       Date:  2012-07       Impact factor: 4.256

4.  Presumed melanoma-associated retinopathy (MAR): a presenting sign of primary small intestinal melanoma?

Authors:  Daniel Rappoport; Hana Leiba
Journal:  Int Ophthalmol       Date:  2012-04-24       Impact factor: 2.031

5.  VEGFR1-mediated pericyte ablation links VEGF and PlGF to cancer-associated retinopathy.

Authors:  Renhai Cao; Yuan Xue; Eva-Maria Hedlund; Zhaodong Zhong; Katerina Tritsaris; Barbara Tondelli; Franco Lucchini; Zhenping Zhu; Steen Dissing; Yihai Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

6.  Molecular biomarkers for autoimmune retinopathies: significance of anti-transducin-alpha autoantibodies.

Authors:  Grazyna Adamus; Lori Brown; Richard G Weleber
Journal:  Exp Mol Pathol       Date:  2009-09-08       Impact factor: 3.362

7.  Beneath the Retinal Pigment Epithelium: Histopathologic Findings in Metastatic Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.

Authors:  Atalie C Thompson; Chad M McCall; Alan D Proia
Journal:  Ocul Oncol Pathol       Date:  2018-06-06

8.  Intravitreal triamcinolone for cancer-associated retinopathy refractory to systemic therapy.

Authors:  Nancy Huynh; Yevgeniy Shildkrot; Ann-Marie Lobo; Lucia Sobrin
Journal:  J Ophthalmic Inflamm Infect       Date:  2012-03-14

9.  Autoantibody against transient receptor potential M1 cation channels of retinal ON bipolar cells in paraneoplastic vitelliform retinopathy.

Authors:  Yujuan Wang; Mones S Abu-Asab; Wei Li; Mary E Aronow; Arun D Singh; Chi-Chao Chan
Journal:  BMC Ophthalmol       Date:  2012-11-13       Impact factor: 2.209

10.  Intravenously administered anti-recoverin antibody alone does not pass through the blood-retinal barrier.

Authors:  Jeong Hun Kim; Jin Hyoung Kim; Dong Hun Kim; Woong-Yang Park; Kyu-Won Kim; Young Suk Yu
Journal:  Korean J Ophthalmol       Date:  2011-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.